Last updated on April 2018

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Brief description of study

This is a randomized, multicenter Phase 3 study of ruxolitinib vs Best Available Therapy in patients with steroid-refractory chronic GVHD after Allogeneic Stem Cell Transplantation.

For more information:

Clinical Study Identifier: TX203013

Find a site near you

Start Over

Incyte Corporation Research Site - Duarte

Located in: Duarte, CA USA
  Connect »